Amgen Inc. is committed to unlocking the potential of biology for patients suffering from serious illnesses by discovering, developing, manufacturing and delivering innovative human therapeutics. This approach begins by using tools like advanced human genetics to unravel the complexities of disease and understand the fundamentals of human biology. Amgen focuses on areas of high unmet medical need and leverages its expertise to strive for solutions that improve health outcomes and dramatically improve people’s lives. A biotechnology pioneer, Amgen has grown to be one of the world’s leading independent biotechnology companies, has reached millions of patients around the world and is developing a pipeline of medicines with breakaway potential. Amgen was incorporated in California in 1980 and became a Delaware corporation in 1987. We have a presence in approximately 100 countries worldwide. Amgen operates in one business segment: human therapeutics.
|Updated||10/27/2020||FCF CAGR 5Y||-1,36%|
|Code||NASDAQ:AMGN||BVPS CAGR 5Y||-15,22%|
|Moat||4||D/E Avg 5Y||1,90|
|Cust. Base||2||EPS/Div. Avg 5Y||2,12|
|Beta||0,74||FCF/Div. Avg 5Y||3,19|
|Div. Streak||9||R&D Avg 5Y||16,89%|
|Div. CAGR 5Y||12,91%||ROA Avg 5Y||9,45%|
|Payout Avg 5Y||66,36%||ROE Avg 5Y||40,58%|
|EPS CAGR 5Y||7,29%||ROIC Avg 5Y||12,77%|
|Revenues||21 662||22 991||22 849||23 747||23 362|
|Earnings||6 939||7 722||1 979||8 394||7 482|
|Equity||28 083||29 875||25 241||12 500||9 673|
|Total Debt||31 556||34 596||35 342||33 929||29 903|
|Payout Ratio %||34,88%||39,06%||171,00%||41,84%||45,03%|
See the Guidelines for more explanations.
See more Companies.